These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 277299)

  • 1. Site of action of methyldopa in lowering the blood pressure in man.
    Kersting F; Reid JL; Dollery CT
    Clin Exp Pharmacol Physiol Suppl; 1978; 4():11-5. PubMed ID: 277299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of central and peripheral mechanisms in the action of alpha-methyldopa on blood pressure and renin secretion.
    Frankel RJ; Reid IA; Ganong WF
    J Pharmacol Exp Ther; 1977 May; 201(2):400-5. PubMed ID: 323462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cardiovascular effects of alpha methyldopa in combination with decarboxylase inhibitors.
    Kersting F; Reid JL; Dollery CT
    Clin Pharmacol Ther; 1977 May; 21(5):547-55. PubMed ID: 322921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of L-dopa and alpha-methyldopa on reflexes and sympathetic nerve function.
    Antonaccio MJ; Robson RD; Burrell R
    Eur J Pharmacol; 1974 Jan; 25(1):9-18. PubMed ID: 4435015
    [No Abstract]   [Full Text] [Related]  

  • 5. Further evidence for a central hypotensive action of -methyldopa.
    Finch L; Haeusler G
    Br J Pharmacol; 1972 May; 45(1):167P-168P. PubMed ID: 5041484
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of centrally mediated hypotensive action of methyldopa and DOPA in cats.
    Torchiana ML; Lotti VJ; Clark CM; Stone CA
    Arch Int Pharmacodyn Ther; 1973 Sep; 205(1):103-13. PubMed ID: 4148405
    [No Abstract]   [Full Text] [Related]  

  • 7. Central inhibitory effect of alpha-methyldopa on blood pressure, heart rate and body temperature of renal hypertensive rats.
    Nijkamp FP; Ezer J; De Jong W
    Eur J Pharmacol; 1975 Apr; 31(2):243-9. PubMed ID: 1149791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between the antihypertensive activity of methyldopa and the appearance of its metabolites in the heart and brain of the hypertensive rat].
    Cohen Y; Wepierre J; Jacquot C; Rapin J
    Arch Int Pharmacodyn Ther; 1974 Feb; 207(2):348-60. PubMed ID: 4827419
    [No Abstract]   [Full Text] [Related]  

  • 9. [The central component of the blood pressure lowering effect of alpha-methyldopa in cats].
    Henning M; van Zwieten PA
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1968; 260(2):140-1. PubMed ID: 4239179
    [No Abstract]   [Full Text] [Related]  

  • 10. Urinary excretion of noradrenaline after treatment with alpha-methyldopa: inhibition by a central nervous mechanism.
    Andén NE; Henning M
    Acta Physiol Scand; 1974 Jan; 90(1):69-72. PubMed ID: 4814544
    [No Abstract]   [Full Text] [Related]  

  • 11. Central cardiovascular effects of L-DOPA and clonidine in the lizard, Agama caudospinosa.
    Johansson P
    Acta Physiol Scand; 1982 Sep; 116(1):37-40. PubMed ID: 7158390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Central nervous sympathetic depressant effects of alpha-methyldopa].
    Tauberger G; Kuhn P
    Naunyn Schmiedebergs Arch Pharmakol; 1971; 268(1):33-43. PubMed ID: 4250102
    [No Abstract]   [Full Text] [Related]  

  • 13. The mechanism of the antihypertensive action of -methyldopa in hypertensive rats.
    Day MD; Roach AG; Whiting RL
    Eur J Pharmacol; 1973 Mar; 21(3):271-80. PubMed ID: 4196583
    [No Abstract]   [Full Text] [Related]  

  • 14. Sites of actions of alpha 2 agonists in the brain and periphery.
    Louis WJ; Jarrott B; Conway EL
    Am J Cardiol; 1988 Feb; 61(7):15D-17D. PubMed ID: 2894151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different dopa decarboxylase inhibitors on the hypotensive response to alpha-methyldopa in rats.
    Henning M
    Br J Pharmacol; 1968 Sep; 34(1):233P-234P. PubMed ID: 5676035
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 17. DOPA decarboxylase activity in the nervous system and the ctenidium of the freshwater clam, Musculium (Sphaerium) transversum.
    Paparo AA; Murphy JA; Dean RC
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1984; 77(1):55-7. PubMed ID: 6141881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the decarboxylase inhibitor benserazide on the antihypertensive effect and metabolism of alpha-methyldopa in patients with essential hypertension.
    Planz G; Gierlichs HW; Hawlina A; Planz R; Stephany W; Rahn KH
    Eur J Clin Pharmacol; 1977 Dec; 12(4):241-5. PubMed ID: 338308
    [No Abstract]   [Full Text] [Related]  

  • 19. A correlation between the hypotensive action of methyldopa and its depression of peripheral sympathetic function.
    Salmon GK; Ireson JD
    Arch Int Pharmacodyn Ther; 1970 Jan; 183(1):60-4. PubMed ID: 5437326
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs.
    Blair ML; Reid IA; Ganong WF
    J Pharmacol Exp Ther; 1977 Jul; 202(1):209-15. PubMed ID: 874815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.